10-Q: Lifecore Biomedical Reports Q2 2026 Financials Amid Revenue Drop

Lifecore Biomedical, Inc. reported a decrease in total revenues and a widening net loss for the second quarter of 2026, impacted by a significant decline in CDMO services.

Summary

• Lifecore Biomedical, Inc. reported total revenues of $34.17 million for the three months ended June 30, 2026, a 6% decrease from $36.44 million in the prior year period.
• For the six months ended June 30, 2026, total revenues were $57.36 million, down 20% from $71.60 million in the comparable prior year period.
• The company reported a net loss of $6.16 million for the three months ended June 30, 2026, compared to a net loss of $1.15 million in the prior year period.
• The net loss for the six months ended June 30, 2026, was $21.14 million, an increase from $15.92 million in the prior year period.
• As of June 30, 2026, the company had $17.24 million in cash and cash equivalents.
• Total debt as of June 30, 2026, was $155.07 million, with $192.73 million outstanding under the Term Loan Credit Facility with Alcon.
• The company received notices of redemption for all 49,263 shares of Series A Redeemable Convertible Preferred Stock, with a redemption date of December 28, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant revenue declines, increased net losses, and substantial debt obligations, despite some operational improvements.

Positives

• HA manufacturing revenues increased by 44% to $18.62 million for the three months ended June 30, 2026, compared to $12.93 million in the prior year period.
• The company implemented a new enterprise resource planning (ERP) system in January 2026 to enhance inventory control, data visibility, and financial management.
• Lifecore expanded its aseptic filling capabilities with the installation of a fully automated high-speed isolator filler in September 2024.
• The company signed a total of 13 programs over the last 12 months, including eight late-stage programs.
• As of June 30, 2026, the company had $21.6 million available for borrowing under its $40.0 million Revolving Credit Facility with no amounts outstanding.
• The company regained compliance with SEC reporting requirements in October 2024 and has been maintaining them.

Negatives

• Total revenues decreased by 6% to $34.17 million for the three months ended June 30, 2026, primarily due to a $8.0 million decrease in CDMO revenue.
• Total revenues decreased by 20% to $57.36 million for the six months ended June 30, 2026, primarily due to a $13.0 million decrease in CDMO revenue.
• Gross profit decreased by 14% to $12.08 million for the three months ended June 30, 2026.
• Gross profit decreased by 31% to $16.54 million for the six months ended June 30, 2026.
• Net loss for the three months ended June 30, 2026, was $6.16 million, an increase from $1.15 million in the prior year period.
• Net loss for the six months ended June 30, 2026, was $21.14 million, an increase from $15.92 million in the prior year period.
• Interest expense, net, increased by 38% to $7.61 million for the three months ended June 30, 2026.
• Interest expense, net, increased by 35% to $14.83 million for the six months ended June 30, 2026.
• The company received notices of redemption for all Series A Redeemable Convertible Preferred Stock, totaling $50.19 million, due December 28, 2026, which the company may not be able to fund.
• A material weakness in internal control over financial reporting related to the legacy ERP environment has not been fully remediated.

Risks

• The company's ability to comply with covenants under its credit agreements and to pay required interest and principal payments when due.
• The company's ability to fund redemptions of shares of the outstanding Series A Redeemable Convertible Preferred Stock in accordance with their terms.
• The timing and amount of future expenses, revenue, cash flow and capital requirements, and timing and availability of and the need for additional financing.
• The impact of macroeconomic events or circumstances on operations and financial performance, including inflation, tariffs, interest rates, social unrest and global instability.
• The outcome and cost of existing and any new litigation or regulatory proceedings.
• The company's ability to maintain or expand relationships with current customers, including the impact of changes in consumer demand or prices for products manufactured for customers.
• The company's ability to grow and diversify its business with new customers, including the potential loss of development customers if they do not receive required funding or regulatory approvals.

Future Outlook

Lifecore expects to further improve efficiencies and productivity through additional procurement and operational strategies, leveraging its new ERP system to strengthen inventory control, support sharper financial management, and help reduce costs. The company expects its current sources of liquidity to be sufficient to finance its operational and capital requirements for at least the next twelve months.

Management Comments

• We have improved operations by expanding our revenue-generating capacity, increasing our focus on manufacturing efficiency and cost management, and investing in systems and processes to support more effective execution.
• We have strengthened our financial position through various actions, including raising capital, extending credit facilities, selling excess equipment, and reducing obligations.
• We enhanced our business development strategy, increased our investment in sales and marketing, and expanded our business development team.
• Lifecore expects to further improve efficiencies and productivity through additional procurement and operational strategies that will build upon the new capabilities and information available from our ERP system.
• The Company intends to seek alternatives that it believes will improve its capital structure for what it expects to be its next phase of growth, and the Company's Board of Directors remains committed to maximizing value for the Company's stockholders, while remaining committed to serving the Company's customers, supporting the Company's employees and growing the business.

Industry Context

StockSavvy.ai notes that Lifecore operates in the highly competitive contract development and manufacturing organization (CDMO) space, which is experiencing growth driven by the increasing complexity of pharmaceutical products and the trend of outsourcing by pharmaceutical companies. However, the company faces challenges related to revenue concentration with key customers and significant debt obligations, which are common pressures in this capital-intensive industry.

Comparison to Industry Standards

• The CDMO sector typically sees revenue growth driven by new client wins and expansion of services. Lifecore's reported 20% revenue decline in the first half of 2026, particularly in its CDMO segment, is significantly below industry growth trends.
• Gross profit margins in the CDMO industry can vary widely based on specialization and scale. Lifecore's gross profit margin of 28.8% for the first half of 2026 is lower than many established CDMOs, especially those focused on high-value sterile injectables.
• Many CDMOs leverage debt financing for expansion, but Lifecore's debt-to-equity ratio appears high, with significant related-party debt, which could be a concern compared to industry peers with more diversified financing structures.
• The industry standard for operational efficiency is continuously improving through automation and ERP systems. Lifecore's implementation of a new ERP system and aseptic filling capabilities aligns with industry best practices for enhancing efficiency and quality.

Legal Proceedings

• An investor dispute filed by 22NW Fund, L.P. concerning alleged material misrepresentations, breaches of contract, and registration delay fees.
• A class action complaint alleging false and misleading statements regarding financial results, internal controls, and financial prospects.
• The company received a subpoena from the SEC regarding a financial statement restatement, which concluded with no action taken against the company.
• Litigation related to the acquisition of Yucatan Foods L.P., involving claims of breach of employment and holdback agreements, fraud, and indemnification.

Related Party Transactions

• Alcon is the company's largest customer (55% of revenues for H1 2026) and largest creditor.
• Alcon provided a Term Loan Credit Facility of $192.7 million outstanding as of June 30, 2026.
• Alcon purchased equipment for $7.73 million in May 2023, which it is leasing back to the company.
• Significant interest expense is incurred from Alcon instruments, including non-cash interest.
• A significant individual prepayment of $5.5 million was made by Alcon in May 2024, accounted for as a contract liability.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss, declining revenues, and the significant debt burden, as well as the potential inability to fund the redemption of preferred stock.
• Creditors may be concerned about the company's ability to service its substantial debt obligations, particularly the related-party debt.
• Employees may be impacted by the ongoing efforts to improve operational efficiency and cost structure, which could include restructuring or headcount adjustments.
• Customers may be affected by the company's focus on operational improvements and potential financial constraints, although the company states its commitment to serving customers.

Next Steps

• The company will begin providing calendar-based comparative periods beginning with its reporting as of and for the periods ended September 30, 2026.
• The company intends to seek alternatives to improve its capital structure for its next phase of growth.
• The company will continue to evaluate strategic alternatives to facilitate the redemption of Redeemable Convertible Preferred Stock.
• The company will continue to execute its remediation plan for the material weakness in internal control over financial reporting.

Key Dates

Recommendation

The filing indicates a worsening financial situation with declining revenues, increasing net losses, and substantial debt, including a significant near-term obligation for preferred stock redemption that the company may struggle to meet. While operational improvements are noted, the overall financial trajectory and the unresolved legal matters present considerable risks, suggesting a sell recommendation.

Keywords

CDMO, Hyaluronic Acid, Pharmaceutical Manufacturing, Sterile Injectables, Contract Development, Fill Finish, Redeemable Preferred Stock, Debt Financing